Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros

Banco de datos
Tipo del documento
Publication year range
3.
Carcinogenesis ; 12(9): 1539-43, 1991 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-1909936

RESUMEN

The metabolism of benzo[a]pyrene (B[a]P) and (-)-transbenzo[a]pyrene-7,8-dihydrodiol (B[a]P-diol) was compared in human mammary epithelial cells (HMEC) grown in serum-free medium, MCDB-170. Conversion of B[a]P-diol to the carcinogen (+)-benzo[a]pyrene-7,8-dihydroxy-9,10-epoxide (BPDE), as measured by analysis of their tetraol hydrolysis products, occurred much more efficiently in cultures incubated with [3H]B[a]P-diol than in cultures incubated with [3H]B[a]P. In cultures pretreated with unlabeled B[a]P (24 h, 400 nM), the conversion of [3H]-B[a]P-diol to [3H]tetraols is inhibited 49%, while the conversion of [3H]B[a]P to [3H]B[a]P-diol- is not affected. These observations led to the identification of a major B[a]P-derived metabolite as 7-hydroxybenzo[a]pyrene (B[a]P-7-ol), which was found to be an extremely potent and selective inhibitor of the conversion of B[a]P-diol to BPDE, with a KI estimated at 3-12 nM. Thus B[a]P activation in HMEC appears to be significantly limited by a feedback inhibition pathway induced by B[a]P-7-ol. The potency and selectivity of the B[a]P-7-ol-induced inhibition suggests that the diol to diolepoxide conversion is affected by a selective oxygenase in HMEC, rather than a non-enzymatic, peroxy radical-induced mechanism. B[a]P-7-ol should prove to be a valuable tool in the study of B[a]P carcinogenesis.


Asunto(s)
Benzo(a)pireno/metabolismo , Mama/metabolismo , Dihidroxidihidrobenzopirenos/metabolismo , 7,8-Dihidro-7,8-dihidroxibenzo(a)pireno 9,10-óxido/metabolismo , 7,8-Dihidro-7,8-dihidroxibenzo(a)pireno 9,10-óxido/farmacocinética , Benzo(a)pireno/farmacocinética , Biotransformación , Mama/citología , Mama/efectos de los fármacos , Carcinógenos/metabolismo , Carcinógenos/farmacocinética , Células Cultivadas , Cromatografía Líquida de Alta Presión , Cromatografía en Capa Delgada , Dihidroxidihidrobenzopirenos/farmacocinética , Células Epiteliales , Epitelio/efectos de los fármacos , Epitelio/metabolismo , Femenino , Humanos
4.
Proc Natl Acad Sci U S A ; 71(6): 2520-4, 1974 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-4366963

RESUMEN

Rifazone-8(2), a new rifamycin derivative, is shown to preferentially inhibit the growth of virus-transformed chick cells in culture. Macromolecular synthesis and glucose uptake of transformed cells are also appreciably decreased in the presence of low concentrations of rifazone-8(2) where the normal cells appear unaffected. While rifazone-8(2) is shown to be a selective inhibitor of RNA-directed DNA polymerase in vitro, its action on the growth of transformed cells may involve some other mechanism.


Asunto(s)
División Celular/efectos de los fármacos , Transformación Celular Neoplásica , Rifamicinas/farmacología , Animales , Virus del Sarcoma Aviar , Células Cultivadas , Embrión de Pollo , ADN Nucleotidiltransferasas , Fibroblastos , Glucosa/metabolismo
6.
Oncology ; 35(2): 76-82, 1978.
Artículo en Inglés | MEDLINE | ID: mdl-652266

RESUMEN

A growth inhibitory effect on adenocarcinoma TA3 ascites tumors in LAF1/J mice resulted from the repeated IP administration of subtoxic doses of 3 rifamycin derivatives: rifampicin (Rif)1, dimethylbenzyldesmethylrifampicin (DMB), and rifazone-82 (R-82). A high-viscosity methylcellulose vehicle was found to be essential for obtaining a uniform drug suspension and a significant antitumor effect by the least water soluble derivatives, DMB and R-82. The more hydrophilic derivative, Rif, was found to have a comparable growth inhibitory effect on TA3 cells when prepared in 0.9% NaCl solution with or without added methylcellulose. Oral or SC drug injections did not have an antitumor effect. The results of this study point to the importance of vehicle and route of administration in chemotherapy trials with these compounds.


Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Rifampin/análogos & derivados , Rifamicinas/uso terapéutico , Administración Oral , Animales , Línea Celular , Inyecciones Intraperitoneales , Inyecciones Subcutáneas , Metilcelulosa , Ratones , Neoplasias Experimentales/tratamiento farmacológico , Vehículos Farmacéuticos , Rifampin/administración & dosificación , Rifampin/uso terapéutico , Rifamicinas/administración & dosificación
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda